Ογ½ΆΚΣΖ΅

Ignacio Garrido-Laguna
( out of 76 reviews )

Ignacio Garrido-Laguna, MD, PhD, MBA

Languages spoken: English, Spanish

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 3A, Gastrointestinal
Salt Lake City
801-585-0250

  • Ignacio Garrido-Laguna, MD, PhD, MBA

    Professor, Ογ½ΆΚΣΖ΅ of Utah School of Medicine

    Director, Phase 1 Program

    Co-leader GI Oncology Multidisciplinary Disease Group

    Expert Panel Metastatic Pancreatic Cancer: ASCO Guideline Update 2020

    Ignacio Garrido-Laguna, MD, PhD, MBA is a Professor of Oncology with tenure at the Ογ½ΆΚΣΖ΅ of Utah School of Medicine and a member of the Experimental Therapeutics Program at Huntsman Cancer Institute (HCI). At HCI, he sees patients with gastrointestinal cancers and patients enrolled in Phase I trials.

    Dr. Garrido-Laguna’s primary research interest is pancreatic ductal adenocarcinoma (PDAC). Since Dr. Garrido-Laguna arrival at HCI in 2011, accrual of PDAC patients to clinical trials has increased from less than 5% in 2011 to consistently 15%. He is PI of multiple clinical trials including novel therapies such as immunotherapies that hold promise in the treatment of this disease. His research team work in drug development in pancreatic cancer is focused on five different areas. They coined the PRIME acronym to refer to these areas (Nevala-Plagemann Nat Rev Clin Oncol 2020). P for Pathway inhibitors, R for DNA Repair agents, I for Immunotherapy, M for drugs targeting cancer metabolism and E for drugs targeting the extracellular matrix. At HCI, patients with pancreatic cancer can participate in clinical trials targeting each of these pancreatic cancer vulnerabilities. In 2018, his team and collaborators reported exceptional responses to entrectinib among patients with advanced pancreatic cancer whose tumors harbored NTRK/ROS1 fusions (Pishvaian et al JCO Precision Oncology 2018). This work was part of an early phase trial that led to FDA approval of entrectinib in patients with solid tumors with NTRK fusions (Doebele et. al Lancet Oncology 2020). In addition, this data contributed to the inclusion of NTRK testing in the recently published ASCO guidelines for metastatic pancreatic cancer (Sohal et al. JCO 2020). While NTRK fusions are very rare events in PDAC (<0.5%), genetic testing to them may render new treatment opportunities for a subset of patients with this recalcitrant disease. In addition, translational work at Huntsman Cancer institute from Aria Vaishnavi (Martin McMahon lab) recently demonstrated that TPR-NTRK fusions were oncogenic in PDAC. More importantly, vertical inhibition of NTRK pathway with entrectinib plus cobimetinib led to sustained inhibition of the pathway and durable responses in xenografts (Vaishnavi et. al Cell Reports 2020).

    Dr. Garrido-Laguna is member of the GI Committee at SWOG. In collaboration with Dr. Sohal from Ογ½ΆΚΣΖ΅ of Cincinnatti and Dr.Beatty from Ογ½ΆΚΣΖ΅ of Pennsylvania, he is conducting a translational medicine study using samples from SWOG1505 to evaluate immunologic predictors of therapeutic response to neoadjuvant therapy for pancreatic cancer.

    He is a Principal Investigator in more than 15 phase 1 clinical trials. This includes an ongoing investigator initiated study to evaluate a RAS signature in patients with KRAS positive metastatic colorectal cancer treated with Folfiri plus a MEK inihibitor.

    Dr. Garrido-Laguna received his medical degree from the School of Medicine of Universidad de Navarra, Pamplona, Spain. He then completed his internship and residency in Internal Medicine-Medical Oncology at Hospital Universitario 12 de Octubre in Madrid, Spain.

    Before joining HCI, Dr. Garrido-Laguna was a clinical fellow in the Phase I program at the Ογ½ΆΚΣΖ΅ of Texas MD Anderson Cancer Center. He completed his postdoctoral fellowship in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. While at Hopkins, he worked extensively in patient derived xenografts. His research showed that stroma (tissue around the tumor that gives nutrition to cancer cells) is involved in resistance to chemotherapy in pancreatic cancer.

    Pancreatic trials decision tree: /huntsmancancerinstitute/clinical-trials/images/pancreatic-cancer-slide.jpg

    Colorectal trials decision tree: /huntsmancancerinstitute/clinical-trials/images/colorectal-cancer-slide.jpg

    GI trials at Hunstman Cancer Institute:

    Avatar mice

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)
    European Society for Medical Oncology
    Ministry of Science and Education of Spain (Medical Oncology)
    National Board of Medical Examiners

    Patient Rating

    4.9 /5
    ( out of 76 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 21, 2024
    HUNTSMAN CANCER CENTER

    I have every confident in my Oncology team

    July 17, 2024
    HUNTSMAN CANCER CENTER

    Sweet good man, with not good news for me, but he was kind and attentive.

    July 12, 2024
    HUNTSMAN CANCER CENTER

    Dr Garrido is an excellent oncologist and we trust him completely.

    June 13, 2024
    HUNTSMAN CANCER CENTER

    I really like that Dr. Garrido is worldly. He is knowledgeable of therapies around the world, not just in the U.S. He and his staff seem very honest and caring. I feel that I am in good hands with them.

    June 12, 2024
    HUNTSMAN CANCER CENTER

    Dr. Garrido-Laguna is a great doctor who has given me the best care I could ask for. He is not only the best oncologist but also a very caring person.

    June 08, 2024
    HUNTSMAN CANCER CENTER

    Careful diagnosis before treatment plan delivered with kindness.

    May 31, 2024
    HUNTSMAN CANCER CENTER

    Ignacio Garrido-Laguna, MD is an extremely talented and knowledgeable doctor in the field of cancer. He was very kind and gracious, and we left our appointment knowing that we would be given any and all possible options to help our family member. He has created an amazing team to work with him and we feel like we have the needed support to find our way during this challenge.

    May 24, 2024
    HUNTSMAN CANCER CENTER

    Lucky to have him as my doctor!

    May 22, 2024
    HUNTSMAN CANCER CENTER

    Dr. Garrido is vary careing when treating his patients. He listen to them, includes them in making decissions regarding there options regarding on best for them.

    See More Patient Comments

  • Ignacio Garrido-Laguna, MD, PhD, MBA

    Professor, Ογ½ΆΚΣΖ΅ of Utah School of Medicine

    Director, Phase 1 Program

    Co-leader GI Oncology Multidisciplinary Disease Group

    Expert Panel Metastatic Pancreatic Cancer: ASCO Guideline Update 2020

    Ignacio Garrido-Laguna, MD, PhD, MBA is a Professor of Oncology with tenure at the Ογ½ΆΚΣΖ΅ of Utah School of Medicine and a member of the Experimental Therapeutics Program at Huntsman Cancer Institute (HCI). At HCI, he sees patients with gastrointestinal cancers and patients enrolled in Phase I trials.

    Dr. Garrido-Laguna’s primary research interest is pancreatic ductal adenocarcinoma (PDAC). Since Dr. Garrido-Laguna arrival at HCI in 2011, accrual of PDAC patients to clinical trials has increased from less than 5% in 2011 to consistently 15%. He is PI of multiple clinical trials including novel therapies such as immunotherapies that hold promise in the treatment of this disease. His research team work in drug development in pancreatic cancer is focused on five different areas. They coined the PRIME acronym to refer to these areas (Nevala-Plagemann Nat Rev Clin Oncol 2020). P for Pathway inhibitors, R for DNA Repair agents, I for Immunotherapy, M for drugs targeting cancer metabolism and E for drugs targeting the extracellular matrix. At HCI, patients with pancreatic cancer can participate in clinical trials targeting each of these pancreatic cancer vulnerabilities. In 2018, his team and collaborators reported exceptional responses to entrectinib among patients with advanced pancreatic cancer whose tumors harbored NTRK/ROS1 fusions (Pishvaian et al JCO Precision Oncology 2018). This work was part of an early phase trial that led to FDA approval of entrectinib in patients with solid tumors with NTRK fusions (Doebele et. al Lancet Oncology 2020). In addition, this data contributed to the inclusion of NTRK testing in the recently published ASCO guidelines for metastatic pancreatic cancer (Sohal et al. JCO 2020). While NTRK fusions are very rare events in PDAC (<0.5%), genetic testing to them may render new treatment opportunities for a subset of patients with this recalcitrant disease. In addition, translational work at Huntsman Cancer institute from Aria Vaishnavi (Martin McMahon lab) recently demonstrated that TPR-NTRK fusions were oncogenic in PDAC. More importantly, vertical inhibition of NTRK pathway with entrectinib plus cobimetinib led to sustained inhibition of the pathway and durable responses in xenografts (Vaishnavi et. al Cell Reports 2020).

    Dr. Garrido-Laguna is member of the GI Committee at SWOG. In collaboration with Dr. Sohal from Ογ½ΆΚΣΖ΅ of Cincinnatti and Dr.Beatty from Ογ½ΆΚΣΖ΅ of Pennsylvania, he is conducting a translational medicine study using samples from SWOG1505 to evaluate immunologic predictors of therapeutic response to neoadjuvant therapy for pancreatic cancer.

    He is a Principal Investigator in more than 15 phase 1 clinical trials. This includes an ongoing investigator initiated study to evaluate a RAS signature in patients with KRAS positive metastatic colorectal cancer treated with Folfiri plus a MEK inihibitor.

    Dr. Garrido-Laguna received his medical degree from the School of Medicine of Universidad de Navarra, Pamplona, Spain. He then completed his internship and residency in Internal Medicine-Medical Oncology at Hospital Universitario 12 de Octubre in Madrid, Spain.

    Before joining HCI, Dr. Garrido-Laguna was a clinical fellow in the Phase I program at the Ογ½ΆΚΣΖ΅ of Texas MD Anderson Cancer Center. He completed his postdoctoral fellowship in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. While at Hopkins, he worked extensively in patient derived xenografts. His research showed that stroma (tissue around the tumor that gives nutrition to cancer cells) is involved in resistance to chemotherapy in pancreatic cancer.

    Pancreatic trials decision tree: /huntsmancancerinstitute/clinical-trials/images/pancreatic-cancer-slide.jpg

    Colorectal trials decision tree: /huntsmancancerinstitute/clinical-trials/images/colorectal-cancer-slide.jpg

    GI trials at Hunstman Cancer Institute:

    Avatar mice

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)
    European Society for Medical Oncology
    Ministry of Science and Education of Spain (Medical Oncology)
    National Board of Medical Examiners

    Education history

    Post Graduate Training Business Administration - David Eccles School of Business Ογ½ΆΚΣΖ΅ of Utah MBA
    Validation of response to gemcitabine in freshly generated pancreatic cancer xenografts - Universidad de Navarra Ph.D.
    Fellowship Investigational Cancer Therapeutics - Ογ½ΆΚΣΖ΅ of Texas MD Anderson Cancer Center Clinical Fellow
    Drug Development in Gastrointestinal Oncology - The Sidney Kimmel Comprehensive Cancer at Johns Hopkins Postdoctoral Fellow
    Residency Internal Medicine-Medical Oncology - Hospital Universitario 12 de Octubre Resident
    Medicine - Universidad de Navarra M.D.

    Selected Publications

    Journal Article

    1. Nevala-Plagemann C, Garrido-Laguna I (2024). NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? Nat Rev Clin Oncol, 21(8), 567-568. ()
    2. Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Gurski LA, Snedeker J, Jones F (2024). Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 22(2 D). ()
    3. Faber EB, Krause HB, Amin K, Walker P, Hosein PJ, Shields AF, Lenz HJ, Prakash A, Goel S, Oberley M, Malleo G, Luchini C, Hwang J, Florou V, Garrido-Laguna I, Lou E (2024). Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets. JCO Precis Oncol, 8, e2300595. ()
    4. Gardner FP, Wainberg ZA, Fountzilas C, Bahary N, Womack MS, Macarulla T, Garrido-Laguna I, Peterson PM, Borazanci E, Johnson M, Ceccarelli M, Pelzer U (2024). Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine Β± Olaratumab in Treatment-NaΓ―ve Participants with Metastatic Pancreatic Cancer. Cancers (Basel), 16(7). ()
    5. Wattenberg MM, Colby S, Garrido-Laguna I, Xue Y, Chang R, Delman D, Lee J, Affolter K, Mulvihill SJ, Beg MS, Wang-Gillam A, Wade JL 3rd, Guthrie KA, Chiorean EG, Ahmad SA, Lowy AM, Philip PA, Sohal DPS, Beatty GL (2024). Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Gastroenterology, 166(6), 1114-1129. ()
    6. Li D, Loriot Y, Burgoyne AM, Cleary JM, Santoro A, Lin D, Aix SP, Garrido-Laguna I, Sudhagoni R, Guo X, Andrianova S, Paulson S (2023). Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021). EClinicalMedicine, 67, 102376. ()
    7. Bauer TM, Santoro A, Lin CC, Garrido-Laguna I, Joerger M, Greil R, Spreafico A, Yau T, Goebeler ME, Htter-Krnke ML, Perotti A, Juif PE, Lu D, Barys L, Cremasco V, Pelletier M, Evans H, Fabre C, Doi T (2023). Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-Ξ² monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. J Immunother Cancer, 11(11). ()
    8. Florou V, Elliott A, Bailey MH, Stone D, Affolter K, Soares HP, Nevala-Plagemann C, Scaife C, Walker P, Korn WM, Lou E, Shroff RT, Hosein PJ, Garrido-Laguna I (2022). Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clin Cancer Res, 29(17), 3408-3417. ()
    9. Beatty GL, Delman D, Yu J, Liu M, Li JH, Zhang L, Lee JW, Chang RB, Bahary N, Kennedy EP, Wang-Gillam A, Rossi GR, Garrido-Laguna I (2023). Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration. Clin Cancer Res, 29(17), 3514-3525. ()
    10. Rodon Ahnert J, Tan DS, Garrido-Laguna I, Harb W, Bessudo A, Beck JT, Rottey S, Bahary N, Kotecki N, Zhu Z, Deng S, Kowalski K, Wei C, Pathan N, Laliberte RJ, Messersmith WA (2023). Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial. ESMO Open, 8(4), 101584. ()
    11. Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, Soares HP, Puri S, Swami U, Wilky B, Hosein P, Trent J, Lopes GL, Park W, Garrido-Laguna I (2023). Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. J Immunother Cancer, 11(8). ()
    12. Moraitis AM, Rose NB, Johnson AF, Dunston ER, Garrido-Laguna I, Hobson P, Barber K, Basen-Engquist K, Coletta AM (2023). Feasibility and acceptability of an mHealth, home-based exercise intervention in colorectal cancer survivors: A pilot randomized controlled trial. PLoS One, 18(6), e0287152. ()
    13. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Hecht JR, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Williams G, Algieri F, Gurski L, Stehman K (2023). Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 21(6), 653-677. ()
    14. Firpo MA, Boucher KM, Bleicher J, Khanderao GD, Rosati A, Poruk KE, Kamal S, Marzullo L, De Marco M, Falco A, Genovese A, Adler JM, De Laurenzi V, Adler DG, Affolter KE, Garrido-Laguna I, Scaife CL, Turco MC, Mulvihill SJ (2023). Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma. JCO Clin Cancer Inform, 7, e2200160. ()
    15. Nevala-Plagemann C, Sama S, Ying J, Shen J, Haaland B, Florou V, Garrido-Laguna I (2022). A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Netw, 21(3), 257-264. ()
    16. Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, Vincent M, Sunakawa Y, Dahan L, Bajor D, Rha SY, Lemech C, Juric D, Rehn M, Ngarmchamnanrith G, Jafarinasabian P, Tran Q, Hong DS (2022). Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med. ()
    17. Powderly JD, Klempner SJ, Naing A, Bendell J, Garrido-Laguna I, Catenacci DVT, Taylor MH, Lee JJ, Zheng F, Zhou F, Gong X, Gowda H, Beatty GL (2022). Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study. Oncologist, 27(11), 905-e848. ()
    18. Hidalgo M, Garcia-Carbonero R, Lim KH, Messersmith WA, Garrido-Laguna I, Borazanci E, Lowy AM, Medina Rodriguez L, Laheru D, Salvador-Barbero B, Malumbres M, Shields DJ, Grossman JE, Huang X, Tammaro M, Martini JF, Yu Y, Kern K, Macarulla T (2022). A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas. Cancer Res Commun, 2(11), 1326-1333. ()
    19. Miotke L, Nevala-Plagemann C, Ying J, Florou V, Haaland B, Garrido-Laguna I (2022). Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. BMC Cancer, 22(1), 1054. ()
    20. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Jeck W, Johung KL, Kirilcuk N, Krishnamurthi S, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Gregory K, Gurski L (2022). Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 20(10), 1139-1167. ()
    21. Parsons M, Lloyd S, Johnson S, Scaife C, Soares H, Kim R, Kim R, Garrido-Laguna I, Tao R (2022). The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. J Gastrointest Cancer, 1-9. ()
    22. Harding JJ, Garrido-Laguna I, Chen X, Basu C, Dowlati A, Forgie A, Hooper AT, Kamperschroer C, Max SI, Moreau A, Shannon M, Wong GY, Hong DS (2022). A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors. Front Immunol, 13, 845417. ()
    23. Naing A, Powderly JD, Nemunaitis JJ, Luke JJ, Mansfield AS, Messersmith WA, Sahebjam S, LoRusso PM, Garrido-Laguna I, Leopold L, Geschwindt R, Ding K, Smith M, Berlin JD (2022). Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer, 10(3). ()
    24. Nevala-Plagemann C, Iyengar S, Trunk AD, Pappas L, Haaland B, Garrido-Laguna I (2022). Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Netw, 20(3), 1-8. ()
    25. Trunk A, Braithwaite M, Nevala-Plagemann C, Pappas L, Haaland B, Garrido-Laguna I (Feb 2022). Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. J Natl Compr Canc Netw, 20(2), 144-150. ()
    26. Chiorean EG, Guthrie KA, Philip PA, Swisher EM, Jalikis F, Pishvaian MJ, Berlin J, Noel MS, Suga JM, Garrido-Laguna I, Cardin DB, Radke MR, Duong M, Bellasea S, Lowy AM, Hochster HS (2021). Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Clin Cancer Res, 27(23), 6314-6322. ()
    27. Mettu NB, Ulahannan SV, Bendell JC, Garrido-Laguna I, Strickler JH, Moore KN, Stagg R, Kapoun AM, Faoro L, Sharma S (2021). A Phase 1a/b Open‑Label, Dose‑Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. ()
    28. Gan HK, Millward M, Jalving M, Garrido-Laguna I, Lickliter JD, Schellens JHM, Lolkema MP, Van Herpen CLM, Hug B, Tang L, OConnor-Semmes R, Gagnon R, Ellis C, Ganji G, Matheny C, Drilon A (2021). A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors. Oncologist, 26(10), e1844-e1853. ()
    29. Foth M, Garrido-Laguna I, Kinsey CG (2021). Therapeutic Targeting of Autophagy in Pancreatic Cancer. Surg Oncol Clin N Am, 30(4), 709-718. ()
    30. Iyengar S, Nevala-Plagemann C, Garrido-Laguna I (2021). Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. Ther Adv Med Oncol, 13, 17588359211045861. ()
    31. Affolter KE, Hellwig S, Nix DA, Bronner MP, Thomas A, Fuertes CL, Hamil CL, Garrido-Laguna I, Scaife CL, Mulvihill SJ, Underhill HR (2021). Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma. Neoplasia, 23(9), 859-869. ()
    32. Baron MK, Wang X, Nevala-Plagemann C, Moser JC, Haaland B, Garrido-Laguna I (2022). Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Pancreas, 50(6), 796-802. ()
    33. Trunk A, Miotke L, Nevala-Plagemann C, Verdaguer H, Macarulla T, Garrido-Laguna I (2021). Emerging Treatment Strategies in Pancreatic Cancer. Pancreas, 50(6), 773-787. ()
    34. Kalasekar SM, Garrido-Laguna I, Evason KJ (2021). Immune Checkpoint Inhibitors in Combinations for Hepatocellular Carcinoma. Hepatology, 73(6), 2591-2593. ()
    35. Florou V, Puri S, Garrido-Laguna I, Wilky BA (2020). Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. Ann Transl Med, 9(12), 1035. ()
    36. Florou V, Nevala-Plagemann C, Whisenant J, Maeda P, Gilcrease GW, Garrido-Laguna I (2021). Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. J Natl Compr Canc Netw, 19(5), 478-482. ()
    37. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA (2021). Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 19(3), 329-359. ()
    38. Parsons M, Lloyd S, Johnson S, Scaife C, Varghese T, Glasgow R, Garrido-Laguna I, Tao R (2020). Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. Ann Surg Oncol, 28(2), 663-675. ()
    39. Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA (2020). Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res, 26(21), 5579-5587. ()
    40. Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, Moravek C, OReilly EM, Philip PA, Pant S, Shah MA, Sahai V, Uronis HE, Zaidi N, Laheru D (2020). Metastatic Pancreatic Cancer: ASCO Guideline Update. J Clin Oncol, JCO2001364. ()
    41. Vaishnavi A, Scherzer MT, Kinsey CG, Parkman GL, Truong A, Ghazi P, Schuman S, Battistone B, Garrido-Laguna I, McMahon M (2019). Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell Rep, 32(5), 107994. ()
    42. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hoffe S, Hubbard J, Hunt S, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gurski LA (2020). NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. J Natl Compr Canc Netw, 18(7), 806-815. ()
    43. Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol.
    44. Florou V, Garrido-Laguna I (2020). Immune Checkpoint Inhibitors in Gastrointestinal Malignancies: What Is the Path Forward? J Immunother Precis Oncol, 3(3), 137-139. ()
    45. Gruhl JD, Garrido-Laguna I, Francis SR, Affolter K, Tao R, Lloyd S (2020). The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer. Cancer Med, 9(5), 1703-1711. ()
    46. Nix DA, Hellwig S, Conley C, Thomas A, Fuertes CL, Hamil CL, Bhetariya PJ, Garrido-Laguna I, Marth GT, Bronner MP, Underhill HR (2020). The stochastic nature of errors in next-generation sequencing of circulating cell-free DNA. PLoS One, 15(2), e0229063. ()
    47. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2019). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol, 17(2), 108-123. ()
    48. Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators (2019). Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol, 21(2), 271-282. ()
    49. Garrido-Laguna I, Krop I, Burris HA 3rd, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong DS (2019). First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer, 145(7), 1798-1808. ()
    50. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming DA, Garrido-Laguna I, Grem JL, Hoffe SE, Hubbard J, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen KS, Saltz LB, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gregory KM, Gurski LA (2019). Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 17(9), 1109-1133. ()
    51. Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I (July 2019). Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO Open, 4(4), e000539.
    52. Swords DS, Francis SR, Lloyd S, Garrido-Laguna I, Mulvihill SJ, Gruhl JD, Christensen MC, Stoddard GJ, Firpo MA, Scaife CL (2018). Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy. J Gastrointest Surg, 23(7), 1401-1413. ()
    53. Weldon Gilcrease G, Stenehjem DD, Wade ML, Weis J, McGregor K, Whisenant J, Boucher KM, Thorne K, Orgain N, Garrido-Laguna I, Sharma S (2018). Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. Invest New Drugs, 37(3), 482-489. ()
    54. Lloyd S, Baraghoshi D, Tao R, Garrido-Laguna I, Gilcrease GW 3rd, Whisenant J, Weis JR, Scaife C, Pickron TB, Huang LC, Monroe MM, Abdelaziz S, Fraser AM, Smith KR, Deshmukh V, Newman M, Rowe KG, Snyder J, Samadder NJ, Hashibe M (2019). Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival. Am J Clin Oncol, 42(4), 355-362. ()
    55. Liang WS, Vergilio J, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku F (2019 Feb). Comprehensive genomic profiling of Hodgkin lymphoma reveals recurrently mutated genes and increased mutation burden. Oncologist, 24(2), 219-228.
    56. Gajiwala S, Torgeson A, Garrido-Laguna I, Kinsey C, Lloyd S (2018). Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. J Gastrointest Oncol, 9(6), 1014-1026. ()
    57. Torgeson A, Tao R, Garrido-Laguna I, Willen B, Dursteler A, Lloyd S (2018). Large database utilization in health outcomes research in pancreatic cancer: an update. J Gastrointest Oncol, 9(6), 996-1004. ()
    58. Pishvaian MJ, Garrido-Laguna I, Liu SV, Multani PS, Chow-Maneval E, Rolfo C (2022). Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer. JCO Precis Oncol, 2, 1-7. ()
    59. Solomon BL, Garrido-Laguna I (2018). TIGIT: a novel immunotherapy target moving from bench to bedside. Cancer Immunol Immunother, 67(11), 1659-1667. ()
    60. Stenehjem DD, Cavalieri CC, Swanson E, Solomon B, Whisenant J, Tran D, Weis J, Gilcrease GW, Sharma S, Garrido-Laguna I (201u). Pembrolizumab in advanced gastrointestinal malignancies with defective dna mismatch repair: A case series. 1(1), 1-6.
    61. Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, Krishnamurthi S, Moravek C, OReilly EM, Philip PA, Ramanathan RK, Ruggiero JT, Shah MA, Urba S, Uronis HE, Lau MW, Laheru D (2018). Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol, 36(24), 2545-2556. ()
    62. Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna I (2018). Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open, 3(5), e000386. ()
    63. Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA (2018). NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw, 16(4), 359-369. ()
    64. Solomon BL, Garrido-Laguna I (2018). Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. Future Oncol, 14(10), 947-962. ()
    65. Torgeson A, Garrido-Laguna I, Tao R, Cannon GM, Scaife CL, Lloyd S (2018). Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. ESMO Open, 3(1), e000282. ()
    66. Torgeson A, Lloyd S, Boothe D, Cannon G, Garrido-Laguna I, Whisenant J, Lewis M, Kim R, Scaife C, Tao R (2017). Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis. Ann Surg Oncol, 24(13), 4001-4008. ()
    67. Torgeson A, Lloyd S, Boothe D, Tao R, Whisenant J, Garrido-Laguna I, Cannon GM (2017). Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. Cancer, 123(19), 3816-3824. ()
    68. Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G Jr, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ (2017). A Phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer, Sep 12; 17(1), 646.
    69. Trang H Au, Kai Wang, David Stenehjem, Ignacio Garrido-Laguna (2017). Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol, 8(3), 387-404.
    70. Tao R, Lloyd S, Burt L, Whisenant J, Garrido-Laguna I, Das P (2017). Pelvic Reirradiation for the Treatment of Locally Recurrent Rectal Cancer. Curr Colorectal Cancer Rep, 13(2), 175-82.
    71. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F (2016). Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 7(41), 67521-67531. ()
    72. Wynn D, Merriman J, Patel AB, Hitchcock YJ, Garrido-Laguna I, Renner D, Clardy SL (2016). Paraneoplastic opsoclonus associated with squamous cell carcinoma of the tongue. Clin Neurol Neurosurg, 149, 11-4. ()
    73. Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R (2016). Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. Mol Cancer Ther, 15(4), 533-47. ()
    74. Patel SB, Gill D, Garrido-Laguna I (2016). Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. Onco Targets Ther, 9, 75-86. ()
    75. Garrido-Laguna I, Hidalgo M (2015). Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol, 12(6), 319-34. ()
    76. Garrido-Laguna I, Tometich D, Hu N, Ying J, Geiersbach K, Whisenant J, Wang K, Ross JS, Sharma S (2015). N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. Oncoscience, 2(3), 285-93. ()
    77. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V (2015). Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. Discov Med, 19(103), 109-16. ()
    78. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V (2015). Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. Discov Med, 19(103), 101-8. ()
    79. Samadder NJ, Curtin K, Wong J, Tuohy TM, Mineau GP, Smith KR, Pimentel R, Pappas L, Boucher K, Garrido-Laguna I, Provenzale D, Burt RW (2014). Epidemiology and familial risk of synchronous and metachronous colorectal cancer: a population-based study in Utah. Clin Gastroenterol Hepatol, 12(12), 2078-84.e1-2. ()
    80. Reese Z, Patel S, Stenehjem DD, Garrido-Laguna I (2014). Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX. J Gastrointest Cancer, 45 Suppl 1, 278-81. ()
    81. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V (2014). Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discov Med, 18(101), 331-9. ()
    82. Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V (2014). Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. Discov Med, 18(101), 323-30. ()
    83. Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R (2014). A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience, 1(10), 614-623. ()
    84. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R (2014). Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer, 120(14), 2164-73. ()
    85. Garrido-Laguna I, McGregor KA, Wade M, Weis J, Gilcrease W, Burr L, Soldi R, Jakubowski L, Davidson C, Morrell G, Olpin JD, Boucher K, Jones D, Sharma S (2013). A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Invest New Drugs, 31(5), 1257-64. ()
    86. Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R (2012). PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget, 3(12), 1566-75. ()
    87. Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R (2012). Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer, 11(4), 297-303. ()
    88. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R (2012). PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol, 30(8), 777-82. ()
    89. Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R (2012). Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer, 118(5), 1422-8. ()
    90. Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R (2012). KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One, 7(5), e38033. ()
    91. Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H, Fendrich V, Rajeshkumar NV, Matsui W, Brossart P, Hidalgo M, Bannerji R, Maitra A, Nelkin BD (2011). Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther, 12(7), 598-609. ()
    92. Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R (2011). Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol, 6(9), 1601-12. ()
    93. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, Hruban RH, Maitra A, Laheru D, Rubio-Viqueira B, Jimeno A, Hidalgo M (2011). Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res, 17(17), 5793-800. ()
    94. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D (2011). A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther, 10(8), 1311-6. ()
    95. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R (2011). PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther, 10(3), 558-65. ()
    96. Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R (2011). Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist, 16(3), 327-35. ()
    97. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R, Hidalgo M (2011). Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther, 10(1), 3-8. ()
    98. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R (2011). PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One, 6(7), e22769. ()
    99. Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R (2010). Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol, 28(31), e633-6. ()
    100. Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, Zhao M, Rajeshkumar NV, Jimeno A, Donehower R, Iacobuzio-Donahue C, Barrett M, Rudek MA, Rubio-Viqueira B, Laheru D, Hidalgo M (2010). Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer, 103(5), 649-55. ()
    101. Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R (2010). Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. Clin Cancer Res, 16(15), 4031-7. ()
    102. Garrido-Laguna I, Amador ML, Ruiz J, Corts-Funes H (2009). Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer. Clin Transl Oncol, 11(3), 183-5. ()
    103. Martin-Santamaria S, Rodriguez JJ, de Pascual-Teresa S, Gordon S, Bengtsson M, Garrido-Laguna I, Rubio-Viqueira B, Lopez-Casas PP, Hidalgo M, de Pascual-Teresa B, Ramos A (2008). New scaffolds for the design of selective estrogen receptor modulators. Org Biomol Chem, 6(19), 3486-96. ()
    104. Garrido-Laguna I, Fernandez Hidalgo O, Garcia Foncillas J (2007). MRI evaluation of breast cancer. N Engl J Med, 357(2), 191; author reply 193. ()
    105. Garrido-Laguna I, Ponz M, Espinos J (2007). Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma? J Clin Oncol, 25(9), 1149; author reply 1149-51. ()

    Review

    1. Garrido-Laguna I, Hidalgo M, Kurzrock R (2011). The inverted pyramid of biomarker-driven trials. [Review]. Nat Rev Clin Oncol, 8(9), 562-6. ()

    Book Chapter

    1. Janku F, Garrido-Laguna I, Kurzrock R (2011). Early-Phase Cancer Clinical Trials: Are the Goals Scientific of Therapeutic? In Am Soc Clin Oncol Educ Book.
    2. Garrido-Laguna I (2009). Targeted Therapies. In Ettinger DS, Donehower RC, Olsen M, Schwartz RN (Eds.), Current Cancer Therapeutics, Springer Editorial (5th).
    3. Garrido-Laguna I (2006). Emergencies in Oncology. In Manual de Diagnostico y Terapeutica Medica Hospital Universitario 12 de Octubre, (Manual of Emergency Ογ½ΆΚΣΖ΅ Hospital 12 de Octubre) (6th). MSD Editorial.

    Case Report

    1. Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol, 4. ()
    2. Rengifo-Cam W, Jasperson K, Garrido-Laguna I, Colman H, Scaife C, Samowitz W, Samadder NJ (2017). A 30-Year-Old Man with Three Primary Malignancies: A Case of Constitutional Mismatch Repair Deficiency. ACG Case Rep J, 4, e34. ()

    Letter

    1. Garrido-Laguna I, Janku F (2012). Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity? [Letter to the editor]. J Clin Oncol, 30(8), 892-3. ()

    Abstract

    1. Abrams TA, Kazmi SMA, Winer IS, Subbiah V, Falchook GS, Reilley M, Kunk PR, Goel S, Garrido-Laguna I, Kochenderfer MD, Werneke S, Andrianova L, Sudhagoni R, Paulson S (Jan 2022). A Phase 1b Multi-tumor Cohort Study of Cabozantinib Plus Atezolizumab in Advanced Solid Tumors (Cosmic -021): Results of the Colorectal Cancer Cohort. [Abstract]. 40(4 Suppl), 121.
    2. Nevala-Plagemann CD, Ying J, Sama S, Florou V, Haaland B, Garrido-Laguna I (2022). A real-world comparison of trifluridine/tipiracil and regorafenib in refractory metastatic colorectal cancer in the United States. [Abstract]. 40(4 Suppl), 39.
    3. Rodon J, Tan DSW, Garrido-Laguna I, Harb W, Beck JT, Bahary N, Rottey S, Zhu Z, Deng S Kowalski K, ONeill G, Wei C, Pathan N, Messersmith WA (Nov 2021). Avelumab + binimetinib in metastatic pancreatic ductal adenocarcinoma (mPDAC): dose-escalation results from the phase 1b/2 JAVELIN PARP MEKi trial [Abstract]. 9(Suppl 2), A371.
    4. Garrido-Laguna I (2021). Phase 1, first-in-human, dose escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654, a PIM kinase inhibitor, in patients with advances solid tumors. [Abstract]. 20(12_suppl), P223.
    5. Gardner F, Wainberg ZA, Fountzilas C, Bahary N, Womack M, Mercada TM, Garrido-Laguna I, Peterson PM, Ceccarelli M, Pelzer U (2021). Results of a randomized, double-blind, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel ± olaratumab in treatment-naïve patients with unresectable metastatic pancreatic cancer [Abstract]. 2021(32 suppl 5), S1084-S1095.
    6. Vaia Florou, Charalampos S Floudas, Asaf Maoz, Abdul Rafeh Naqash, Gregory Hildebrand, Ethan Sokol, Garrett M Frampton, Sonam Puri, Umang Swami, Breelyn A Wilky, Peter Joel Hosein, Jonathan C Trent, Gilberto Lopes, Wungki Park, Ignacio Garrido-Laguna (ASCO 2021). Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with low tumor mutational burden (TMB). [Abstract]. 39(2021), (suppl 15: abstr 2599).
    7. Sohal D, Duong MT, Chang R, Xue Y, Delman D, Garrido-Laguna I, Mulvihill SJ, Affolter K, Washington MK, Beg MS, Wang-Gillam A, Wade JL, Gandhi N, Ahmad SA, Lowy AM, Chiorean EG, Guthrie KA, Hochster HS, Philip PA, Beatty GL (2021). Immunologic predictors of therapeutic response to neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDA) in SWOG S1505. [Abstract]. 39(2021), (suppl 3; abstr 419).
    8. Miotke L, Nevala-Plagemann CD, Ying J, Florou V, Haaland B, Garrido-Laguna I (2021). Real-world outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma. [Abstract]. 39(2021), (suppl 3: abstr 387).
    9. Parsons M, Lloyd S, Johnson SB, Scaife CL, Garrido-Laguna I, Tao R (2021). The implications of treatment delays in adjuvant therapy for cholangiocarcinoma patients. [Abstract]. 39(2021), (suppl 3: abstr 291).
    10. Vaishnavi A, Scherzer M, Kinsey C, Garrido-Laguna I, McMahon M (2020). Combined TRKA and MEK1/2 Inhibition Forestalls the Onset of Acquired Resistance in a New Preclinical Model of NTRK1+ Pancreatic Cancer. [Abstract].
    11. Florou V, Nevala-Plagemann C, Barber K, Mastroianni J, Cavalieri C, Garrido-Laguna I (June 2020). Immune checkpoint inhibition re-challenge after a planned treatment interruption in patients with pancreatic adenocarcinoma with mismatch repair deficient tumors. [Abstract]. (2021) 39(suppl_15 abstr), 2599.
    12. Florou V, Nevala-Plagemann C, Mulvihill S, Garrido-Laguna I (June 2020). Pancreatic acinar carcinoma - a rare entity with a targetable BRAF V600E mutation. [Abstract]. Proceedings of the American Association for Cancer Research, June 2020.
    13. Braithwaite M, Nevala-Plagemann CD, Baron K, Haaland B, Pappas LM, Garrido-Laguna I (May 2020). Real-world outcomes of patients with BRAF-mutated mCRC treated in the United States. [Abstract]. 38(suppl; abstr 4030 American Society of Clinical Oncology Annual Meeting).
    14. Garrido-Laguna I, Dillon PM, Anthony SP, Janat-Amsbury M, Ashenbramer N, Warner SL, Mouritsen L, Wade ML, Whatcott C, Bearss D, Fu S (Mary 2020). A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑3654 administered daily for 28 days to patients with advanced solid tumors. [Abstract]. May 2020.
    15. Meric-Bernstam F, Calvo E, Moreno V, Chung HC, Park YH, Bang Y-J, Rosen LS, Mita MM, Garrido-Laguna I, Leung ACF, Dube H, Zhong W, Chen X, Dawaher R, Curigliano G (May 2020). A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF‑06804103) in patients with HER2-positive solid tumors. [Abstract]. 38(suppl; abstr 1039 American Society of Clinical Oncology Annual Meeting).
    16. Pauley K, Koptiuch C, Greenberg S, Gammon A, Nevala-Plagemann C, Vagher J, Espinel W, Gilcrease GW, Kohlmann W, Garrido-Laguna I (2020). Case series examining somatic test results for patients with hereditary cancer syndromes associated with gastrointestinal cancer risk [Abstract]. 38(2020), (suppl 4; abstr 680).
    17. Baron K, Nevala-Plagemann CD, Moser J, Haaland B, Wang X, Garrido-Laguna I (2020). Survival outcomes based on sequence of therapy using FOLFIRINOX and nab-paclitaxel + gemcitabine in metastatic pancreatic ductal adenocarcinoma [Abstract]. 38(2020), (suppl 4; abstr 657).
    18. Parsons M, Tao R, Lloyd S, Johnson SB, Scaife CL, Garrido-Laguna I, Varghese T (2020). Refusal of surgery results in inferior survival in esophageal cancer [Abstract]. 38(2020), (suppl 4; abstr 364).
    19. Siena S, Demetri G, Doebele R, Chae Y, Conkling P, Garrido-Laguna I, Garrido P, Rolfo C, Sigal D, Eng S, Simmons B, Ye C, Ciardiello F (July 2019). Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001) [Abstract]. 2019(Abstract #0-024).
    20. Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I (Jul 2019). Survival of patients with metastatic HER2 positive gastroesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on frontline chemotherapy plus trastuzumab [Abstract]. J Clin Oncol, 4(4), e000539.
    21. Chiorean EG, Guthrie KA, Philip PA, Swisher EM, Jalikis F, Pishvaian MJ, Berlin J, Noel MS, Suga JM, Garrido-Laguna I, Cardin DB, Lew DL, Lowy AM, Hochster HS (2019 Annual ASCO Meeting). Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513 [Abstract]. 37(2019), (suppl; abstr 4014).
    22. Vaishnavi A, Scherzer M, Kinsey C, Garrido-Laguna I, McMahon M (2019). MEK1/2 Inhibition Forestalls the Onset of Acquired Resistance to Entrectinib in a New Preclinical Model of TPR-NTRK1 Driven Pancreatic Cancer [Abstract].
    23. Gruhl J, Francis SR, Tao R, Solomon BL, Nevala-Plagemann CD, Garrido-Laguna I, Lloyd S (01/18/2019). The impact of histology (adenocarcinoma vs. SCC) on outcomes in nonmetastatic pancreatic cancer.Presented ASCO 2019 Gastrointestinal Cancers Symposium [Abstract]. J Clin Oncol, 37(2019), suppl 4 abstr 419.
    24. Pelzer U, Bendell JC, Womack MS, Bahary N, Macarulla T, Borazanci EH, Levy DE, Mo G, Ramage SC, Garrido-Laguna I (01/18/2019). A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.Presented AASCO 2019 Gastrointestinal Cancers Symposium [Abstract]. J Clin Oncol, 37(2019), suppl 4; abstr 330.
    25. Sharma S, Moore KN, Mettu NB, Garrido-Laguna I, Ulahannan SV, Khemka V, Kapoun A, Faoro L, Bendell J (Nov 2018). Initial results from a phase 1a/b study of etigilimab (OMP-313M32), an anti-T cell immunoreceptor with lg and ITIM domains (TIGIT) antibody, in advanced solid tumors [Abstract]. SITC 2018, Washington, D.C.
    26. Bahary N, Wang-Gillam A, Haraldsdottir S, Somer BG, Lee JS, ORourke MA, Nayak-Kapoor A, Beatty GL, Liu M, Delman D, Rossi GR, Kennedy EP, Vahanian NN, Link CJ, Garrido-Laguna I (2018 ASCO Annual Meeting). Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer. [Abstract]. J Clin Oncol 36, 2018 (suppl; abstr 4015).
    27. Swords DS, Garrido-Laguna I, Mulvihill SJ, Stoddard GJ, Firpo MA, Scaife CL (January 2018). Association of adjuvant chemotherapy with overall survival in resected pancreatic adenocarcinoma previously treated with neoadjuvant therapy. [Abstract]. J Clin Oncol 36, 2018 (suppl 4S; abstr 404).
    28. Bendell JC, Pelzer U, Womack MS, Borazanci EH, Bahary N, Garrido-Laguna I, Maur M, Prater T, Levy DE, Cronier D, Ramage S, Macarulla T, Cannon S (January 2018). A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer. [Abstract]. J Clin Oncol 36, 2018 (suppl 4S; abstr TPS524).
    29. Pishvaian MJ, Rolfo CD, Liu SV, Multani PS, Maneval EC, Garrido-Laguna I (January 2018). Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions. [Abstract]. J Clin Oncol 36, 2018 (suppl 4S., abstr 521).
    30. Nevala-Plagemann CD, Francis S, Cavalieri CC, LLoyd S, Garrido-Laguna I (January 2018). The effect of adjuvant chemotherapy in patients without local nodal metastases following neoadjuvant chemoradiotherapy and esophagectomy for locally advanced esophageal cancer. [Abstract]. J Clin Oncol 36, 2018 (suppl 4S; abstr 111).
    31. Francis S, Nevala-Plagemann CD, Cavalieri CC, Lloyd S, Garrido-Laguna I (January 2018). Postoperative chemotherapy in patients who are pN+ following neoadjuvant chemoradiation for locally advanced esophageal cancer. [Abstract]. J Clin Oncol 36, 2018 (suppl 4S, abstr 97).
    32. Garrido-Laguna I, Krop IE, Burris H, Hamilton EP, Braiteh FS, Weise A, Abu-Khalaf MM, Zopf C, Lakshminarayanan M, Holland JS, Baffa R, Hong DS (2017). A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer. Presented at the 2017 ASCO Annual Meeting on June 5, 2017. [Abstract]. J Clin Oncol, 35(suppl; abstr 2511).
    33. Cavalieri CC, Swanson E, Whisenant JR, Weis JR, Gilcrease GW, Stenehjem DD, Sharma S, Garrido-Laguna I (Jan 2017). Pembroliuzmab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience. Presented at the 2017 Gastrointestinal Cancers Symposium, Poster Session C: Cancers of the Colon, Rectum, and Anus. [Abstract]. J Clin Oncology, 35(suppl 4S; abstract 792).
    34. D Stenehjem, S Gupta, M Wade, G Gilcrease, I Garrido-Laguna, JR Weis, J Whisenant, S Sharma (1 Oct 2016). A phase I dose escalation trial to assess the safety and preliminary efficacy of mFOLFOX6 combined with pembrolizumab (MK3475) in advanced gastrointestinal malignancies [Abstract]. Ann Oncol, 27(suppl_6), 1071.
    35. Nathan Bahary, Ignacio Garrido-Laguna, Andrea Wang-Gillam, Asha Nyak-Kapoor, Eugene Kennedy, Nicholas N Vahanian, Charles J Link (2016). Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer. [Abstract]. J Clin Oncol 34, 2016 (suppl 4S; abstr 452).
    36. DS Hong, I Garrido-Laguna, IE Krop, V Subbiah, TL Werner, CM Cotter, EP Hamilton, K Velastegui, D Xuan, R Bugarini, A Gollerkeri, HA Burris (2015). First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors. ASCO Annual Meeting May 29-June 2,2015 (Abst. # to be released on May 13th) [Abstract].
    37. H Park, I Garrido-Laguna, A Naing, S Fu, GS Falchook, SA Piha-Paul, JJ Wheler, DS Hong, V Subbiah, AM Tsimberidou, AO Kaseb, Y Oki, R Zinner, S Patel, V Velez Bravo, MA Fanale, F Meric Bernstam, R Kurzrock, F Janku (2015). Phase 1 study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies. ASCO Annual Meeting May 29-June 2,2015 [Abstract]. J Clin Oncol, 33, 2015(suppl; abstr 2584)).
    38. K Wang, A Johnson, I Garrido-Laguna, J Chmielecki, R Yelensky, D Lipson, JA Elvin, JA Vergilio, SA Ali, V Miller, PJ Stephens, JS Ross (2015). Amplification of CRKL in human cancer: a rare event associated with potential sensitivity to targeted therapy. ASCO Annual Meeting May 29-June 2,2015. Abstract Number: 1526 [Abstract]. J Clin Oncol, 33, 2015(suppl; abstr 1526).
    39. WS Liang, B Salhia, A Helland, S Sekar, I Garrido-Laguna, M Fanale, Y Oki, JR Westin, RE Davis, F Meric-Bernstam, F Janku (2015). Identification of mutations in histrone modification genes in Hodgkin lymphoma. AACR 106th Annual Meeting, April 18-22 (LB-176) [Abstract].
    40. Shiven B Patel, Danielle Tometich, Zachary L Reese, Sunil Sharma, Ignacio Garrido-Laguna (2015). Exceptional responses in patients with metastatic colorectal cancer enrolled in first-in-man studies from 2002 through 2012. Presented at the 2015 Gastrointestinal Cancers Symposium [Abstract]. J Clin Oncol, 33(suppl 3 abstr 687).
    41. Zachary L Reese, Danielle Tometich, Shiven B Patel, Sunil Sharma, Ignacio Garrido-Laguna (2015). Exceptional responses in patients with upper gastrointestinal malignancies enrolled in first-in-man studies: 2002-2012. Presented at the 2015 Gastrointestinal Cancers Symposium., Abstract 311 [Abstract]. J Clin Oncol, 33(suppl 3), abstr 311.
    42. Shepard D, Bruce J, Garrido-Laguna I, et al (2014). Phase Ib study of axitinib in combination with crizotinib in patients with advanced solid tumors [Abstract]. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4596).
    43. Reynolds K, Juric D, Baselga J, Garrido-Laguna I, Bang, Y et al (2014). A Phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer or HER2-overexpressing metastatic breast or gastric cancer [Abstract]. J Clin Oncol 32:5s, 2014 (suppl; abstr 2517), 2014 ASCO Annual Meeting.
    44. Garrido-Laguna I, Tometich D, Hu Nan, Boucher K, Sharma S (2014). N of 1 Case Reports of Exceptional Responders Among Pancreatic Cancer Patients Enrolled in First-in-man studies from 2002 through 2012. Pancreatic Cancer: Innovation in Research and Treatment 2014 New Orleans, abst # B93 [Abstract]. 2(3), 285-293.
    45. Janku F, Garrido-Laguna I, Velez-Bravo V et al (2013). Significant activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients [Abstract]. Blood (ASH Annual Meeting Abstracts), 122(21), 3048.
    46. Samadder NJ, Curtin K, Wong J, Pappas L, Tuohy T, Mineau G, Smith K, Pimentel R, Boucher K, Garrido-Laguna I, Provenzale D, Burt, R (2013). Epidemiology and Familial Risk of Synchronous and Metachronous Colorectal Cancer: A Population-based Study in Utah. Abs P599, ACG Annual Meeting, San Diego 2013 [Abstract].
    47. Garrido-Laguna I, McGregor K, Wade M, et al (6/9/2012). Testing targeted demethylation to overcome resistance to epidermal growth factor receptor (EGFR) blocking agents in wild-type (wt) KRAS metastatic colorectal cancer patients (mCRC). 2012 ASCO Annual Meeting, Chicago, IL. (Abstract number 3057) [Abstract]. 30(15_suppl), 3057.
    48. Garrido-Laguna I, Kurzrock R, Wheler JJ, Falchook GS, Piha-Paul SA, Fu S, Naing A, Hinojosa C, Mistry R, Scamardo A, Culotta KS, Ekmekcioglu S, Wen S, Camacho LH, Ivy SP, Hong DS (2011). Dual inhibition of VEGF pathway: Phase I trial of bevacizumab and cediranib in advanced solid tumors. [Abstract]. J Clin Oncol, 29(15_suppl), 3065. ()
    49. Janku F, Garrido-Laguna I, Wheler JJ, Hong DS, Naing A, Falchook GS, Fu S, Moulder SL, Luthra R, Lee JJ, Tsimberidou AM, Kurzrock R (2011). Screening for PIK3CA mutations, PTEN loss, and RAS/RAF mutations in early-phase protocols with PI3K/mTOR pathway inhibitors. [Abstract]. J Clin Oncol, 29(15_suppl), 10507. ()
    50. Garrido-Laguna I, Janku F, Falchook GS, et al (2011). KRAS mutations in colorectal cancer may predict a pattern of organ-specific metastasis. AACR 102nd Annual Meeting, April 2-6, 2011; Orlando, FL. (Abstract # 2264) [Abstract].
    51. Janku F, Garrido-Laguna I, Hong DS et al (2011). Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors. AACR 102nd Annual Meeting 2011; April 2-6, 2011; Orlando, FL (Abstract #1279) [Abstract].
    52. Garrido-Laguna I, Janku F, Falchook GS, Naing A, Fu S, Wheler J, Tsimberidou AM, Hong DS, Kurzrock R (Feb 2011). Retrospective study to elucidate a K-ras phenotype in patients with colorectal cancer.PMID: 27985389 [Abstract]. J Clin Oncol, 29(4_suppl), 462.
    53. Janku F, Garrido-Laguna I, Tsimberidou A, et al (2011). Screening for PIK3CA Mutations, PTEN Loss and RAS/RAF mutations in Early-Phase Protocols with PI3K/mTOR Pathway Inhibitors. 2011 ASCO Annual Meeting, Chicago, IL. (Abstract No: 10507) [Abstract].
    54. Garrido-Laguna I, Kurzrock R, Falchook GS, et al (2011). Dual inhibition of VEGF pathway: Phase 1 trial of bevacizumab and cediranib in advanced solid tumors. 2011 ASCO Annual Meeting, Chicago, IL. (Abstract No: 3057) [Abstract].
    55. Janku F, Tsimberidou A, Garrido-Laguna I et al (2010). Screening for PIK3CA, Ras and Raf mutations in trials with PI3K/Akt/mTOR signaling pathway inhibitors. 22nd EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics”, Berlin [Abstract].
    56. Garrido-Laguna I, Janku F, Falchook GS, et al (2010). Clinical outcomes of patients with advanced head and neck tumors enrolled in phase I trials is not inferior to outcomes with last treatment line based on an FDA-approved drug. AACR 101st Annual Meeting, April 17-21, 2010, Washington, DC. (Abst #2773) [Abstract].
    57. Garrido-Laguna I, Rudek M, Tan A, Uson M, Iacobuzio-Donahue C, Angenendt M, Jimeno A, Laheru D, Barret M, Hidalgo M (May 2009). Preclinical identification of biomarkers of response to mTOR inhibitors and subsequent application in a phase II trial of sirolimus in pancreatic cancer patients refractory to gemcitabine.PMID: 27964189 [Abstract]. J Clin Oncol, 27(15_suppl), 4612.
    58. Tan A, Jimeno A, Garrido-Laguna I, Uson M, De Oliveira E, Wilson A, Rubio-Viqueira B, Rajeshkumar NV, Hidalgo M (May 2009). Use of amolecular mimicry approach to identify effective agents in pancreatic cancer.PMID: 27964150 [Abstract]. J Clin Oncol, 27(15_suppl), 4603.
    59. Hidalgo M, Garrido-Laguna I, Uson M, De Oliveira E, Schulick R, Hruban RH, Maitra A, Jimeno A, Rubio-Viqueira B, Rajeshkumar NV (May 2009). Activity of gemcitabine in direct patient-derived xenografts and clinical outcome: Validation of an in vivo model for drug development.PMID: 27962716 [Abstract]. J Clin Oncol, 27(15_suppl), 4528.
    60. Janku F, Garrido-Laguna I, Hong D, Tsimberidou A, et al (2009). PIK3CA mutations in patients with advanced cancers treated in phase I clinical trials. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. B134). Boston [Abstract].
    61. Rajeshkumar NV, De Oliveira E, Ottenhof N, Garrido-LagunaI I, et al (2009). MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions in pancreatic tumor xenografts. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. A251). Boston [Abstract].
    62. Mishra A, Feldmann G, Garrido-Laguna I, Dadon T, Strock C, Bannerji R, Hidalgo M, Maitra A, Nelkin B (2009). SCH727965, a novel potent cyclin dependent kinase inhibitor, inhibits pancreatic tumor growth and Ras-mediated tumorigenic signaling. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. A243). Boston [Abstract].
    63. Hidalgo M, Strawn S, Wick M, Rajeshkumar NV, Garrido-Laguna I, Sidranski D, Bruckheimer E (2009). From mice to men: Guiding cancer treatment through Personalized Tumorgraft models results in prolongued clinical responses in patients with refractory advanced cancers and discovery of novel predictive biomarkers. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. A19). Boston [Abstract].
    64. Maitra A, Rajeskhumar NV, Rudek M, Garrido-Laguna I, Laheru D, Iglesias J, Desai N, Von Hoff D, Hidalgo M (2009). Nab-paclitaxel targets tumor stroma and results, combined with gemcitabine, in high efficacy against pancreatic models. C246. AACR-NCI-EORTC Molecular Targets in Cancer Therapeutics (Abst. C246). Boston [Abstract].
    65. Garrido-Laguna I, Tan AC, Villarroel MC, Angenendt M, Pastori W, Rajeshkumar NV, Ciomei M, Jimeno A, Rubio-Viqueira B, Hidalgo M (2009). Activity of PHA-848125 in pancreatic cancer xenografts is related to downregulation of S6 via p53 pathway. AACR 100th Annual Meeting in Denver (Permanent abst number 1798). [Abstract].
    66. Villaroel MC, Tan AC, Garrido-Laguna I, Rubio-Viqueira B, De Oliveira E, Rajeshkumar NV, Jimeno A, Hidalgo M (2009). Orthotopic cancer models are better predictors of clinical response than s.c. models. AACR 100th Annual Meeting in Denver (Permanent abst number 2320). [Abstract].

    Other

    1. Solomon BL, Garrido-Laguna I (1/11/2018). Novel Therapies in Pancreatic Cancer: Opportunities and Challenges for Precision Medicine. 2018 Gastrointestinal Cancers Symposium Daily News (January 11, 2018). San Francisco.

  • News & Podcasts

    News

    Huntsman Cancer Institute News